Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C B Nelson

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Archives of General Psychiatry|January 1, 1994
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity SurveyR C Kessler, K A McGonagle, S Zhao, et al.
Nature Reviews. Microbiology|January 8, 2005
Meningococcal meningitisT Aguado, E Bertherat, M Djingarey, et al.
Journal of Medicinal Chemistry|February 13, 1999
Identification and characterization of m1 selective muscarinic receptor antagonists1C E Augelli-Szafran, C J Blankley, J C Jaen, et al.
Journal of Medicinal Chemistry|June 23, 1999
Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivativesS S Nikam, J J Cordon, D F Ortwine, et al.
Journal of Medicinal Chemistry|September 15, 1995
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activityC F Bigge, T C Malone, P A Boxer, et al.
Pharmacology, Biochemistry, and Behavior|February 26, 1998
Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonistA E Corbin, T A Pugsley, H C Akunne, et al.
Journal of Medicinal Chemistry|July 3, 1998
Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonistH Tecle, S D Barrett, D J Lauffer, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Archives of General Psychiatry|January 1, 1994
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity SurveyR C Kessler, K A McGonagle, S Zhao, et al.
Nature Reviews. Microbiology|January 8, 2005
Meningococcal meningitisT Aguado, E Bertherat, M Djingarey, et al.
Journal of Medicinal Chemistry|February 13, 1999
Identification and characterization of m1 selective muscarinic receptor antagonists1C E Augelli-Szafran, C J Blankley, J C Jaen, et al.
Journal of Medicinal Chemistry|June 23, 1999
Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivativesS S Nikam, J J Cordon, D F Ortwine, et al.
Journal of Medicinal Chemistry|September 15, 1995
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activityC F Bigge, T C Malone, P A Boxer, et al.
Pharmacology, Biochemistry, and Behavior|February 26, 1998
Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonistA E Corbin, T A Pugsley, H C Akunne, et al.
Journal of Medicinal Chemistry|July 3, 1998
Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonistH Tecle, S D Barrett, D J Lauffer, et al.
Pageof 4